Rapport Therapeutics (RAPP) Enterprise Value (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Enterprise Value data on file, last reported at -$476.8 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 726.18% year-over-year to -$476.8 million in Q1 2026; TTM through Mar 2026 was -$476.8 million, a 726.18% decrease from a year earlier, with the FY2025 full-year figure at -$52.8 million, up 82.72% from the prior year.
• Enterprise Value for Q1 2026 stood at -$476.8 million, down from -$52.8 million in the prior quarter.
• Over the last five years, Enterprise Value for RAPP reached as high as -$39.4 million in Q3 2024 and fell as low as -$513.1 million in Q3 2025.
• Historically, Enterprise Value has averaged -$200.4 million across 4 years, with a median of -$94.9 million in 2023.
• On a YoY basis, Enterprise Value climbed as much as 82.72% in 2025 and fell as far as 1201.67% in 2025.
• Year by year, Enterprise Value stood at -$70.3 million in 2023, then sank by 334.54% to -$305.3 million in 2024, then surged by 82.72% to -$52.8 million in 2025, then slumped by 803.85% to -$476.8 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$476.8 million in Q1 2026, -$52.8 million in Q4 2025, and -$513.1 million in Q3 2025.